Guide

Net operating loss (NOL) carryforwards explained

Harbor Biotech traded at 2.1x EV/sales in early 2026 despite burning cash on Phase II trials. Bulls pointed to $420M of federal net operating loss carryforwards disclosed in Note 14 — a “hidden asset” worth roughly $88M at a 21% statutory rate. The equity research team initially added the full deferred tax asset (DTA) to enterprise value, lifting implied per-share value by $1.40. After modeling Section 382 limitations from a 2024 ownership change, the 80% annual taxable-income cap on post-2017 NOLs, and a partial valuation allowance management had already booked, usable tax shields fell from $420M nominal to $122M expected present value. The DCF premium over peers shrank from 28% to 4%. NOLs are real economic attributes — but headline balance-sheet numbers overstate how much they are worth to a new shareholder.

A net operating loss (NOL) arises when a company's tax-deductible expenses exceed taxable income in a given year. Instead of wasting the deduction, tax systems let firms carry the loss forward (and sometimes back) to offset future profits, reducing cash taxes later. On US GAAP financials, expected future tax savings appear as a deferred tax asset (DTA), often paired with a valuation allowance when realization is uncertain. This guide covers how NOLs are created and consumed, where they appear in filings, post-TCJA rule changes, Section 382 ownership-change limits, NOL valuation in DCF models, the Harbor Biotech refactor, a technique decision table versus cash-tax analysis, pitfalls, and an investor checklist.

How NOLs are created and used

At a high level, taxable income for a US corporation equals revenue minus deductible expenses — including operating costs, interest, depreciation, and certain credits — subject to permanent and temporary book-tax differences. When deductions exceed income, the company records a NOL for tax purposes even if GAAP net income is positive (book-tax gaps are common).

Carryforward lets the company apply past NOLs against future taxable income, lowering cash taxes in profitable years. Carryback (limited under current US rules) lets firms apply losses to prior years and claim refunds. The economic value of an NOL is therefore the present value of expected future tax savings — not the face amount of the loss.

Cash tax savings show up on the cash flow statement under operating activities as changes in deferred taxes, but the balance-sheet DTA is where investors first spot large NOL stockpiles. Pair NOL work with the financial statements guide to trace book income, taxable income, and cash taxes through the three statements.

Where NOLs appear on the balance sheet

Under ASC 740, a company recognizes a DTA when it expects future taxable income sufficient to realize the benefit. NOL-related DTAs typically sit in “deferred tax assets — net operating loss carryforwards” in the 10-K tax footnote, alongside credits, stock-compensation timing differences, and lease liabilities.

The critical offset is the valuation allowance: a contra-asset reducing the DTA when management judges realization is not “more likely than not.” Early-stage biotech, turnaround stories, and chronic loss-makers often carry allowances equal to most or all of their NOL DTAs. Investors who add gross DTAs to valuation without reading the allowance line double-count risk already acknowledged by auditors.

When a company turns profitable, you may see the allowance release as a large one-time tax benefit boosting GAAP earnings per share (EPS). That release is non-cash and can distort earnings quality metrics — separate recurring operating profit from allowance reversals when screening cheap stocks on P/E.

US tax rules investors should know

The Tax Cuts and Jobs Act (TCJA) changed NOL mechanics materially. Key points for US filers (always confirm with current law and company counsel):

NOLs arising after 2017 can generally be carried forward indefinitely but may only offset 80% of taxable income in any given year (no carryback for most corporates under TCJA, with limited exceptions during COVID-era relief that has largely expired).
Pre-2018 NOLs remain subject to the old 20-year expiration schedule and can typically offset 100% of taxable income until used or expired. Mature companies may have mixed “NOL buckets” with different rules.
State NOLs follow separate statutes — some states conform to federal rules; others impose lower caps, shorter carry periods, or suspended deductions. A federal DTA model that ignores state friction overstates value for multi-state operators.

The 80% cap means a company with $100M taxable income and unlimited NOLs still pays tax on $20M of income at the statutory rate. High-margin businesses that suddenly inflect to profit may consume NOLs more slowly than a simple “NOL balance ÷ tax rate” shortcut suggests.

Section 382 and ownership-change limits

IRC Section 382 limits NOL usability after an ownership change — generally when 5% shareholders increase their collective ownership by more than 50 percentage points over a rolling three-year period. Mergers, PIPE financings, activist accumulations, and bankruptcy reorganizations frequently trigger 382 studies.

When triggered, annual NOL usage is capped at:

Section 382 Limit = Fair Market Value of Equity at Change × Federal Long-Term Tax-Exempt Rate

Excess NOLs may expire unused if the company cannot generate enough taxable income within the carry period. Acquirers sometimes structure deals to preserve NOLs; others explicitly write them down as worthless post-change. Harbor Biotech's 2024 crossover financing shifted 58% of ownership in 18 months, capping annual federal NOL usage at roughly $14M — far below the run-rate taxable income bulls assumed at FDA approval.

Read the tax footnote for “ownership change,” “382,” or “annual limitation” language. If absent but the cap table moved violently, ask whether a study was performed — immaterial disclosures still destroy DCF assumptions.

Valuing NOLs in models and M&A

Do not capitalize the full DTA at face value. A workable approach:

Start with federal and state NOL balances from the tax footnote, split by vintage (pre- vs post-TCJA) and expiration schedule.
Apply Section 382 annual limits and ownership-change haircuts.
Project taxable income (or EBITDA-to-taxable-income bridge) under base, bull, and bear cases.
Model annual NOL absorption respecting the 80% cap and expirations.
Discount expected tax savings at an appropriate rate (often WACC or a tax-adjusted cost of debt) and compare to the booked DTA net of valuation allowance.

In M&A, NOLs can reduce the acquirer's combined cash taxes — but only if the target's attributes survive 382, the deal structure permits combination, and the buyer can generate US taxable income. Strategic buyers with existing profits value NOLs higher than financial sponsors with pass-through structures or offshore domiciles.

For equity screens, compare enterprise value to operating metrics without adding DTAs unless you have built the absorption schedule. Enterprise value already reflects market expectations; stuffing unmodeled NOLs into sum-of-the-parts valuations is a common source of false cheapness.

NOLs and free cash flow

NOLs affect cash taxes, not operating cash flow before taxes in most presentations. When a company uses NOLs, cash taxes fall while GAAP tax expense may look “normal” because deferred tax assets amortize on the income statement. That widens the gap between net income and free cash flow (FCF) in early profitable years.

In a DCF, reflect NOLs in the cash-tax line of your forecast — not as a separate equity add-on at the end. Double-counting (lower cash taxes in the forecast and adding the full DTA to terminal equity value) inflates fair value. Terminal-year cash taxes should assume NOLs are exhausted or capped, returning to full statutory rates unless new losses accrue.

Harbor Biotech refactor

Harbor's 2025 10-K disclosed $420M federal NOLs and a $315M valuation allowance, leaving $105M net DTA. Bulls used $420M × 21% ≈ $88M equity uplift; bears noted the allowance and Phase III binary risk.

The refactor:

Engaged public 382 analysis: $14M annual usage cap post-2024 ownership change.
Modeled FDA approval in 2028 with ramping taxable income, applying 80% caps on post-2017 NOLs and 20-year expiry on legacy buckets.
Probability-weighted approval at 55%; haircut NOL PV further for delay and failure scenarios.
Reconciled modeled PV ($122M) to net DTA ($105M) — close enough to trust management's allowance; gross $420M was misleading.

Result: the name moved from “cheap on hidden NOL asset” to “option on approval with modest tax tailwind.” False positives in the biotech NOL screen dropped from 9 tickers to 2. The lesson: always convert headline NOL balances into an absorption schedule before adding them to valuation.

Technique decision table

Question	Use NOL analysis when…	Consider alternatives when…
Is the stock cheap?	Large NOL/DTA footnote; imminent profitability inflection	Stable cash taxpayer with negligible DTAs
Modeling cash taxes in DCF	Forecast turns profitable within NOL carry period	Perpetual loss-maker; allowance equals gross DTA
M&A synergy case	Acquirer has US taxable income; 382 limit still binding	Pass-through buyer or offshore re-domicile planned
Screening earnings quality	Separate allowance release from core EPS	No tax footnote volatility
Credit analysis	NOLs do not pay interest; focus on cash burn	NOL value is equity upside, not liquidity

Common pitfalls

Capitalizing gross NOL balance at statutory rate — ignores allowances, 382 caps, and 80% annual limits.
Ignoring valuation allowance — management may already have marked DTAs as unrealizable.
Assuming instant full utilization at profitability — high growth with thin early profits consumes NOLs slowly.
Missing ownership-change triggers — PIPEs and roll-ups can slash annual usability overnight.
Using P/E on allowance-release quarters — distorts trailing multiples.
Double-counting in DCF — lower forecast cash taxes plus full DTA add-on.
Forgetting state NOL friction — federal models alone overstate combined savings.
Treating NOLs as liquidity — they do not fund payroll or debt service until profits arrive.

Investor checklist

Pull federal and state NOL balances and expiration tables from the tax footnote.
Note gross DTA, valuation allowance, and net DTA for NOL carryforwards.
Search for Section 382, ownership change, or annual limitation disclosures.
Identify NOL vintage mix (pre-2018 vs post-2017) and applicable 80% caps.
Build a taxable-income forecast with bull/base/bear scenarios.
Model annual NOL absorption with caps, expirations, and 382 limits.
Discount expected tax savings and reconcile to net DTA on the balance sheet.
Separate allowance releases from core EPS in earnings-quality screens.
Reflect NOLs in DCF cash-tax lines, not as a duplicate equity kicker.
For M&A, stress-test combined taxable income and attribute limitations.
Check state conformity rules if state NOLs are material.
Revisit assumptions after any financing that shifts 5% shareholder ownership.

Key takeaways

NOLs are deferred tax deductions; their value equals the present value of future cash tax savings, not the headline loss balance.
DTAs and valuation allowances on the balance sheet tell you whether management thinks NOLs are realizable.
Section 382 and the 80% taxable-income cap can sharply reduce how fast NOLs convert into cash.
Harbor Biotech's refactor cut perceived NOL equity uplift from $88M face-value math to $122M probability-weighted PV — and exposed $298M of nominal NOLs as effectively stranded.
Model NOLs inside cash-tax forecasts; pair with earnings quality and FCF analysis rather than adding gross DTAs to enterprise value.